Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.

  title={Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.},
  author={Eva Versteijne and M. Suker and Karin B. C. Groothuis and Janine M Akkermans-Vogelaar and Marc G. Besselink and Bert A. Bonsing and Jeroen Buijsen and Olivier R C Busch and Geert-Jan M. Creemers and Ronald M van Dam and Ferry A.L.M. Eskens and Sebastiaan Festen and Jan Willem B. de Groot and Bas Groot Koerkamp and Ignace de Hingh and Marjolein Y V Homs and Jeanin E. van Hooft and Emile D. Kerver and Saskia A. C. Luelmo and Karen J Neelis and Joost Jan Nuyttens and Gabriel Paardekooper and Gijs A. Patijn and Maurice J. C. van der Sangen and Judith de Vos-Geelen and Johanna W. Wilmink and Aeilko H. Zwinderman and Cornelis J. A. Punt and Casper H.J. van Eijck and Geertjan van Tienhoven},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
PURPOSE Preoperative chemoradiotherapy may improve the radical resection rate for resectable or borderline resectable pancreatic cancer, but the overall benefit is unproven. PATIENTS AND METHODS In this randomized phase III trial in 16 centers, patients with resectable or borderline resectable pancreatic cancer were randomly assigned to receive preoperative chemoradiotherapy, which consisted of 3 courses of gemcitabine, the second combined with 15 × 2.4 Gy radiotherapy, followed by surgery… 

Figures and Tables from this paper

Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial

Neoadjuvant gem citabine-based chemoradiotherapy followed by surgery and adjuvant gemcitabine improves OS compared with upfront surgery and adenovation in resectables and borderline resectable pancreatic cancer.

Surgical Complications in a Multicenter Randomized Trial Comparing Preoperative Chemoradiotherapy and Immediate Surgery in Patients With Resectable and Borderline Resectable Pancreatic Cancer (PREOPANC Trial)

Preoperative chemoradiotherapy did not increase the incidence of surgical complications or mortality and reduced the rate of postoperative pancreatic fistula after resection in patients with (borderline-)resectable pancreatic cancer.

Is Neoadjuvant Therapy Needed in Patients with Resectable Pancreatic Cancer?

  • D. Kim
  • Medicine
    Gut and liver
  • 2022
It is assumed that neoadjuvant therapy in patients with resectable disease could prolong PFS although selection bias still exists because this is a retrospective study and there was no difference in overall survival between the two groups.

Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using capecitabine-based versus gemcitabine-based concurrent chemotherapy.

This hypothesis-generating study suggests concurrent CAPE may be a more effective radiosensitizer than GEM for patients with (B)RPC.

Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial

The PREOPANC-2 trial investigates whether neoadjuvant FOLFIRINOX improves OS compared with neoadvuvant gemcitabine-based chemoradiotherapy and adjuvant gem citabine in resectables and borderline resectable pancreatic cancer patients.

Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer: A Phase II Open-Label Multicenter Prospective Trial (JASPAC05).

S-1 and concurrent radiotherapy appear to be feasible and effective at increasing the R0 resection rate and improving survival in patients with BRPC.

Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?

The evidence from randomized studies shows that overall survival by intention-to-treat improves after neoadjuvant gemcitabine-based chemoradiotherapy or chemotherapy (various regimens), as compared to immediate surgery followed by adjuvant chemotherapy.

Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy

Although there is no standard NAT regimen for patients with pancreatic cancer, postoperative chemotherapy following NAT and resection appears to be associated with improved OS for patientsWith node-positive disease.

Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity

The authors report long-term outcomes for BRPC/LAPC patients explored after treatment with either nCT alone or nCT followed by five-fraction SBRT (nCT-SBRT), which remained associated with R0 resection and experienced similar survival outcomes compared with the n CT alone cohort.

Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis

On multivariable analysis in pancreatic cancer stages I and II, including age, sex, borderline or resectable disease, CA 19–9, positive lymph nodes and neoadjuvant treatment, the surgery was the only factor associated with improved overall survival (p = 0.04).



Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets

Neoadjuvant chemoradiation was feasible, safe, and efficacious, although non-significant results were obtained as a result of the underpowered data due to the difficulty in recruiting patients.

Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer

This worldwide first randomized trial for neoadjuvant chemoradiation is safe with respect to toxicity, perioperative morbidity, and mortality showed that neoadjoint chemoradiotherapy in pancreatic cancer is safe.

Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial

Preoperative FOLFIRINOX followed by individualized chemoradiotherapy in borderline resectable pancreatic cancer results in high rates of R0 resection and prolonged median PFS and median OS, supporting ongoing phase 3 trials.

Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial

The PREOPANC phase III trial aims to test the hypothesis that median overall survival of patients with resectable or borderline resectables pancreatic cancer can be improved with preoperative radiochemotherapy, and investigates whether preoperative Radiochemotherapy improves overall survival by means of increased resection rates.

Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial

Compared to upfront surgery, neoadjuvant chemoradiation provides oncological benefits in patients with BRPC, and this is the first prospective randomized controlled trial on the oncology benefits of neoadedjuvant treatment in BRPC.

Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05).

A randomized, controlled trial has begun to compare neoadjuvant chemotherapy using gemcitabine and S-1 with upfront surgery for patients planned resection of pancreatic cancer. Patients were enrolled

Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)

The NEOPAC study will determine the efficacy of neoadjuvant chemotherapy in pancreatic cancer for the first time and offers a unique potential for translational research.

Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) – study protocol for a national multicentre randomized controlled trial

The NorPACT–1 trial aims to test the hypothesis that overall mortality at one year after allocation of treatment can be reduced with neoadjuvant chemotherapy in surgically treated patients with resectable pancreatic cancer.

Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score Adjusted Analysis

Patients who received preoperative CRT were more likely to undergo a margin negative and node negative resection and experience less locoregional recurrence and similar OS compared with preoperative chemotherapy.

Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial.

There were no safety issues in the FFX arm regarding surgical complications, so neoadjuvant/ perioperative treatment approach seems to be feasible, subjected to the small number of pts in the study.